Seeking Alpha

Response Genetics tumbles after Q3 results

  • Response Genetics (RGDX -24.1%) plunges after Q3 revenue comes in short of expectations at $4.1M.
  • Pharmaceutical client revenue — which the company notes is "characteristically inconsistent" — falls 35% Y/Y and 30% sequentially. The company blames "one-time $500K milestone payments received in both Q2 and in Q3 2012."
  • ResponseDX revenue: -16% Y/Y, -18% Q/Q. Here, the company says the culprit is "accelerated refocusing of sales efforts on larger new potential accounts."
  • Gross margin: 33% versus 49% in Q3 2012 and 49% in Q2 2013.
  • CEO Thomas Bologna calls the results "clearly disappointing." (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: